Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
46 Results Found
AHA Letter of Support for the Mapping America's Pharmaceutical Supply Chain, or MAPS, Act of 2023
Hospitals and health systems share concern about chronic and increasing drug shortages that have serious consequences for patient safety, quality of care and access to therapies. Addressing drug shortages is complex and costly to hospitals and health systems in terms of staff time and other resources required to manage the shortages.
Civica Rx Gets More Backing in Effort to Reduce Drug Prices and Shortages
The state of California put up $50 million to have Civica Rx manufacture and distribute low-cost biosimilars for the three most used short- and long-acting insulins.
3 Ways Pharma Could Jolt Health Care in 2023
The market for biosimilar drugs to treat cancer, inflammatory diseases, diabetes and more will continue to expand, ideally resulting in lower prices as more pharmaceutical patents expire and competitors enter the market.
FDA updates ibuprofen compounding guidance
The Food and Drug Administration yesterday revised its recent guidance for outsourcing facilities compounding certain ibuprofen oral suspension products.
The Future of Health System-based Cancer Care – Advances, Opportunities and Challenges
Hosted by the American Hospital Association in partnership with McKesson
4 Key Predictions for Health Care in 2023 and How to Respond
In 2023, provider organizations can expect significant evolutionary changes in how to optimize patient engagement, the ever-expanding role that retail clinics will play in care delivery and some upheaval in venture capital funding for health care startups.
AMA study: Pharmacy benefit manager market highly concentrated, integrated with insurers
The market for pharmacy benefit manager services is highly concentrated, with commercial insurers often sharing ownership in the PBM, according to the analysis.
FTC launches inquiry into prescription drug middlemen
The FTC will launch an inquiry into the prescription drug middleman industry.
[Special Edition]: Insurers’ “White Bagging” Drug Policy Threatens Patient Safety
Increases in consolidation and alignment between commercial health plans and pharmacy benefit managers have resulted in a series of business practices designed to steer patients to insurer-affiliated pharmacies and away from patients’ longstanding providers to the detriment of patient care.
AHA to FTC Re: Request for Public Comment on the Impact of Pharmacy Benefit Managers’ Practice
The AHA urges the FTC to increase scrutiny on insurer-mandated white bagging policies, as well as the impact of PBM-negotiated rebates and other business practices on the 340B drug discount pricing program and overall drug prices and drug price increases.